COMPOSITION FOR USE IN THE PROMOTION OF INTESTINAL ANGIOGENESIS AND OF NUTRIENT ABSORPTION AND OF ENTERAL FEEDING TOLERANCE AND/OR IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL INFLAMMATION AND/OR IN THE RECOVERY AFTER INTESTINAL INJURY AND SURGERY
The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation, such as necrotizing enterocolis, and/or in the recovery after intestinal injury and/or surgery. This composition is particularly adapted for use in infants, notably preterm infants.
1 . A method for the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and/or surgery comprising administering to an individual in need of same a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides, the mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide.
2 . A method according to claim 1 , wherein the neutral oligosaccharide is selected from the group consisting of fructooligosaccharides (FOS) and galactooligosaccharides (GOS), preferably GOS.
3 . A method according to claim 1 , wherein the oligosaccharide mixture contains at least one N-acetylated oligosaccharide selected from the group comprising consisting of GalNAcα1,3Galβ1,4Glc (=3′GalNAc-lac=N-acetyl-galactosaminyl-lactose), Galβ1,6GalNAcα1,3Galβ1,4Glc (=6′Gal-3GalNAc-lac=galactosyl-N-acetyl-galactosaminyl-lactose), Galβ1,4GlcNAcβ1,3Galβ1,4Glc (lacto-N-neotetraose or LNnT) and Galβ1,3GlcNAcβ1,3Galβ1,4Glc (lacto-N-tetraose or LNT), at least one sialylated oligosaccharide selected from the group consisting of NeuAcα2,3Galβ1,4Glc (=3′-sialyllactose) and NeuAcα2,6Galβ1,4Glc (=6′-sialyllactose), and at least one neutral oligosaccharide selected form the group consisting of Galβ1,6Gal (=β1,6-digalactoside); Galβ1,6Galβ1,4Glc (=6′Gal-lac); Galβ1,6Galβ1,6Glc; Galβ1,3Galβ1,3Glc; Galβ1,3Galβ1,4Glc (=3′Gal-lac); Galβ1,6Galβ1,6Galβ1,4Glc (=6′,6-diGal-lac); Galβ1,6Galβ1,3Galβ1,4Glc (=6′,3-diGal-lac); Galβ1,3Galβ1,6Galβ1,4Glc (=3′,6-diGal-lac); Galβ1,3Galβ1,3Galβ1,4Glc (=3′,3-diGal-lac); Galβ1,4Galβ1,4Glc (=4′ Gal-lac) and Galβ1,4Galβ1,4Galβ1,4Glc (=4′,4-diGal-lac); and Fucα1,2Galβ1,4Glc (=2′ fucosyllactose or FL).
4 . A method according to claim 1 , wherein the oligosaccharide mixture comprises:
0.25-20 wt %, preferably 0.3-10 wt % of at least one N-acetylated oligosaccharide;
0.5-30 wt %, preferably 0.75-15 wt % with respect to the total weight of the oligosaccharide mixture, of at least one sialylated oligosaccharide, and
50-99.3 wt % with respect to the total weight of the oligosaccharide mixture, of at least one neutral oligosaccharide.
5 . A method according to claim 1 , wherein the oligosaccharide mixture is present in an amount of 0.5-70% with respect to the total weight of the composition.
6 . A method according to claim 1 , wherein the LC-PUFA is selected from the group consisting of arachidonic acid (ARA) and docosahexanoic acid (DHA).
7 . A method according to claim 1 , wherein the probiotic is a probiotic bacterial strain.
8 . A method according to claim 1 , wherein the N-acetylated oligosaccharide is selected from the group consisting of lacto-N-neotetraose (or LNnT) and lacto-N-tetraose (or LNT).
9 . A method according to claim 1 , wherein the sialylated oligosaccharide is selected from the group consisting of 3′-sialyllactose and 6′-sialyllactose.
10 . A method according to claim 1 , wherein the neutral oligosaccharide is 2′-fucosyllactose (or FL).
11 . A method according to claim 1 , wherein the composition is in a form selected from the group consisting of a preterm infant formula, a human milk fortifier, a starter infant formula, a follow-on formula, a baby food formula, an infant cereal formula, a growing-up milk, a medical food product for clinical nutrition and a supplement.
12 . A method according to claim 1 , wherein the individual is an infant or child.
13 . A method for the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and/or surgery comprising administering to an individual in need of same a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides, the mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, as a synthetic nutritional agent.